-

10:37:32 AM

GNPX Stock News

GNPX - Genprex Inc

06/02/23 10:15 AM

Nasdaq : GNPX

clinical trial

Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial

AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is working

RHEA-AI

very positive

05/30/23 7:30 AM

Nasdaq : GNPX

clinical trial

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 portion of the Acclaim-1...

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : GNPX

clinical trial

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

RHEA-AI

neutral

05/23/23 7:30 AM

Nasdaq : GNPX

clinical trial

Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System

Genprex, Inc., a clinical-stage gene therapy company...

RHEA-AI

neutral

05/08/23 7:30 AM

Nasdaq : GNPX

conferences

Genprex to Participate and Present at Upcoming May Industry and Investor Conferences

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming industry and investor...

RHEA-AI

neutral

04/19/23 9:11 AM

Nasdaq : GNPX

clinical trial

Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene. "We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery...

RHEA-AI

very positive

04/18/23 9:11 AM

Nasdaq : GNPX

Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma

Pre-clinical Study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivoStudy adds to the growing body of research examining TUSC2 as a target for multiple other cancersTUSC2 is the tumor suppressor

RHEA-AI

neutral

03/23/23 7:30 AM

Nasdaq : GNPX

Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

Rodney Varner, CEO of Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today commended The U.S. Food and Drug Administration's initiative that aims to expedite the development of gene therapies for patients with rare diseases. "The FDA's efforts to streamline the...

RHEA-AI

neutral

03/13/23 7:30 AM

Nasdaq : GNPX

conferences

Genprex to Present at Bioprocessing Summit Conference

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona,...

RHEA-AI

neutral

03/08/23 7:30 AM

Nasdaq : GNPX

conferences

Genprex to Participate in March Investor and Industry Conferences

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in March 2023. In attendance at the Roth Conference will be Genprex's Chief Financial Officer, Ryan...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

GNPX Data

IndustryPharmaceutical Preparation Manufacturing
Websitegenprex.com
CeoJ. Rodney Varner
Security nameGenprex Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1601 Trinity St Bldg B
StateTexas
CityAustin
Zip78712-1765
CountryUS
Phone15125377997

About Genprex Inc

genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur